In a study was led by Dr. Jianxin Jiang (Institute of Department of Trauma Medical Center, Daping Hospital, State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University), a team screened a highly selective kinase inhibitor library and found that CP-673451 can upregulate BTLA expression on immunocytes and reduce sepsis-related mortality.